Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6-24) for Patients with Relapsed and Refractory Multiple Myeloma in the Karmma Clinical Trial

Introduction: Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy, is approved by the US FDA for the treatment of adult patients (pts) with relapsed and refractory multiple myeloma (RRMM) after ≥ 4 prior lines of therapy, including an immunomodulatory agent, proteasome inhibitor (PI), and anti-CD38 antibody. In the pivotal, phase 2, single-arm KarMMa trial, ide-cel showed frequent, deep, and durable responses in pts with RRMM who were triple-class exposed to immunomodulatory drugs, PIs and anti-CD38 antibodies (Munshi NC, et al. NEJM 2021;384:705-716). To understand the pts' perspective on the advantages and disadvantages of ide-cel treatment that may not be captured by established health-related quality of life (HRQoL) questionnaires, a series of qualitative pt interviews were embedded into the KarMMa trial. This analysis focuses on time points between 6 and 24 months following treatment with ide-cel, providing an update on previously reported pt perspectives (Braverman J, et al. J Clin Oncol 2020;38(suppl 29). Abstract 155; Braverman J, et al. Value Health 2021;24(suppl 1). Abstract S61).